FDA Approves Stealth’s Barth Syndrome Therapy: First Mitochondria-Targeted Treatment

The FDA granted approval to Stealth BioTherapeutics’ Barth syndrome therapy, marking the first mitochondria-targeted treatment for this rare genetic disorder. This regulatory milestone offers a novel therapeutic option for patients with a disease that previously lacked effective treatments, emphasizing advancements in targeting mitochondrial dysfunction therapeutically.